Cardiac effects of current treatments of chronic obstructive pulmonary disease

The Lancet. Respiratory Medicine
Lies LahousseGuy G Brusselle

Abstract

We review the cardiac safety of the drugs available at present for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in stable disease, focusing on inhaled long-acting muscarinic antagonists (LAMA) and long-acting β2 agonists (LABA), used either as a monotherapy or as a fixed-dose combination. We report the difficulties of, and pitfalls in, the investigation of the safety of drug treatments in COPD, which is hampered by the so-called COPD trial paradox: on the one hand, COPD is defined as a systemic disease and is frequently associated with comorbidities (especially cardiovascular comorbidities), which have an important effect on the prognosis of individual patients; on the other hand, patients with COPD and cardiovascular or other coexisting illnesses are often excluded from participation in randomised controlled clinical trials. In these trials, inhaled long-acting bronchodilators, both LAMA or LABA, or both, seem to be safe when used in the appropriate dose in adherent patients with COPD without uncontrolled cardiovascular disease or other notable comorbidities. However, the cardiac safety of LAMA and LABA is less evident when used inappropriately (eg, overdosing) or in patients with COPD and substant...Continue Reading

References

Jan 1, 1995·Neurourology and Urodynamics·D A CanningR M Levin
Feb 1, 1996·Journal of Clinical Epidemiology·R D MannL Wilton
Mar 11, 2000·American Journal of Respiratory and Critical Care Medicine·D H AuB M Psaty
Dec 12, 2001·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·D M Newnham
Aug 3, 2002·American Journal of Respiratory and Critical Care Medicine·Nicholas R AnthonisenUNKNOWN Lung Health Study Research Group
Sep 23, 2003·BMJ : British Medical Journal·R Graham BarrCarlos A Camargo
Nov 4, 2004·American Heart Journal·David H AuUNKNOWN ACQUIP Investigators
Apr 13, 2005·Epidemiology·Consuelo HuertaLuis A García Rodríguez
Jan 18, 2006·Journal of the American College of Cardiology·Sabine M J M StrausJacqueline C M Witteman
Dec 2, 2006·The European Respiratory Journal·D D SinA G Agusti
Feb 23, 2007·The New England Journal of Medicine·Peter M A CalverleyUNKNOWN TORCH investigators
Nov 30, 2007·The New England Journal of Medicine·Jerry Avorn
Jun 27, 2008·The European Respiratory Journal·D M ManninoF Holguin
Oct 7, 2008·The New England Journal of Medicine·Donald P TashkinUNKNOWN UPLIFT Study Investigators
May 8, 2009·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Françoise Van Bambeke, Paul M Tulkens
Sep 1, 2009·Lancet·Peter M A CalverleyUNKNOWN M2-124 and M2-125 study groups
Sep 5, 2009·American Journal of Respiratory and Critical Care Medicine·Bartolome CelliUNKNOWN UPLIFT Study Investigators
Dec 1, 2002·Expert Review of Pharmacoeconomics & Outcomes Research·Sabina A Antoniu, Traian Mihaescu
Jul 21, 2010·British Journal of Clinical Pharmacology·Charlotte van NoordBruno H Ch Stricker
Aug 6, 2010·Thorax·Peter M A CalverleyUNKNOWN TORCH Investigators
Sep 17, 2010·The New England Journal of Medicine·Theresa M MicheleSolomon Iyasu
Mar 13, 2012·The European Respiratory Journal·Mutsuo YamayaShoji Kudoh
May 9, 2012·American Journal of Respiratory and Critical Care Medicine·Miguel DivoUNKNOWN BODE Collaborative Group
May 18, 2012·The New England Journal of Medicine·Wayne A RayC Michael Stein
Aug 11, 2012·American Journal of Respiratory and Critical Care Medicine·Jørgen VestboRoberto Rodriguez-Roisin
Sep 29, 2012·The European Respiratory Journal·Jørgen VestboDavid E Newby
Jan 26, 2013·American Journal of Respiratory and Critical Care Medicine·Mario CazzolaM Gabriella Matera
Feb 5, 2013·International Journal of Chronic Obstructive Pulmonary Disease·Marc L DecramerBarbara P Yawn

❮ Previous
Next ❯

Citations

May 29, 2016·Trends in Cardiovascular Medicine·Marten E van den BergLies Lahousse
Nov 2, 2016·The Lancet. Respiratory Medicine·Lowie E G W VanfleterenFrits M E Franssen
Sep 3, 2016·American Journal of Respiratory and Critical Care Medicine·Sara RoversiAlvar Agustí
Apr 12, 2017·Postgraduate Medicine·Nicola A HananiaBarbara P Yawn
Mar 6, 2018·Expert Opinion on Drug Safety·Maria Gabriella MateraMario Cazzola
May 19, 2018·Expert Review of Respiratory Medicine·Edward Kerwin, Gary T Ferguson
Feb 2, 2019·Expert Opinion on Pharmacotherapy·Paola RoglianiJosuel Ora
Aug 11, 2017·European Respiratory Review : an Official Journal of the European Respiratory Society·Salvatore CorraoFrancesco Perticone
May 26, 2017·The European Respiratory Journal·Nera Agabiti, Giuseppe Maria Corbo
May 26, 2017·The European Respiratory Journal·Samy SuissaPierre Ernst
Oct 5, 2018·European Respiratory Review : an Official Journal of the European Respiratory Society·Klaus F RabeSamy Suissa
Jun 7, 2019·Drugs & Aging·Roy A PleasantsH Edward Davidson
Aug 12, 2019·Respirology : Official Journal of the Asian Pacific Society of Respirology·Lianne ParkinJack Dummer
Oct 31, 2019·Respirology : Official Journal of the Asian Pacific Society of Respirology·Shakti D ShuklaPhilip M Hansbro
Aug 18, 2020·Internal and Emergency Medicine·Morohunfolu AkinnusiAli Albert El-Solh
Aug 28, 2020·International Journal of Chronic Obstructive Pulmonary Disease·Stefan AndreasPeter Alter
Jan 23, 2018·Therapeutic Advances in Respiratory Disease·Ann D MorganJennifer K Quint
Aug 15, 2017·European Journal of Heart Failure·Helgo MagnussenStephan Rosenkranz
Sep 19, 2019·Kardiologiia·Z R AisanovE N Kalmanova
Apr 29, 2021·International Journal of Chronic Obstructive Pulmonary Disease·Nirupama PutchaSanjay Sharma
Aug 21, 2021·European Respiratory Review : an Official Journal of the European Respiratory Society·Dave SinghFernando J Martinez
Sep 28, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Pierachille SantusDejan Radovanovic
Oct 9, 2021·NPJ Primary Care Respiratory Medicine·Donald P TashkinShahin Sanjar
Sep 28, 2017·Respiratory Medicine·Pietro PirinaUNKNOWN COPD-HF Study Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

International Journal of Chronic Obstructive Pulmonary Disease
Wijdan H RamadanSarah A Al Assir
International Journal of Chronic Obstructive Pulmonary Disease
Marc L DecramerBarbara P Yawn
Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine
Stan Ejiofor, Alice M Turner
© 2022 Meta ULC. All rights reserved